The development and utilization of immune-checkpoint inhibitors that target CTLA4, PD-1, and PD-L1 have had a transformative impact on the field of cancer therapy, as acknowledged by the 2018 Nobel Prize in Medicine and Physiology (Braun et al., 2021; Kraehenbuehl et al., 2022), This has introduced a novel immunotherapy strategy with promising potential for treating cancer. Here, CTLA4 is linked to cancer.